Table 1 Patient information
Subjects | Number | Female/male | Age (years) ± SD | Type MS | DMT |
|---|---|---|---|---|---|
HC | Total 10 | 4/6 | 40 ± 12 |  |  |
1 | Female | 25 | – | – | |
2 | Female | 49 | – | – | |
3 | Female | 25 | – | – | |
4 | Female | 46 | – | – | |
5 | Male | 50 | – | – | |
6 | Male | 42 | – | – | |
7 | Male | 30 | – | – | |
8 | Male | 39 | – | – | |
9 | Male | 33 | – | – | |
10 | Male | 60 | – | – | |
MS | Total 15 | 8/7 | 45 ± 16 |  |  |
11 | Female | 73 | PP-MS | Untreated | |
12 | Male | 51 | PP-MS | Untreated | |
13 | Male | 56 | PP-MS | Untreated | |
14 | Female | 25 | RR-MS | Interferon beta-1a | |
15 | Female | 71 | RR-MS | Untreated | |
16 | Female | 24 | RR-MS | Glatiramer acetate | |
17 | Female | 49 | RR-MS | Glatiramer acetate | |
18 | Male | 30 | RR-MS | Interferon beta-1a | |
19 | Male | 48 | RR-MS | Natalizumab | |
20 | Female | 30 | RR-MS | Untreated | |
21 | Female | 32 | RR-MS | Untreated | |
22 | Female | 46 | RR-MS | Untreated | |
23 | Male | 45 | RR-MS | Untreated | |
24 | Male | 58 | RR-MS | Untreated | |
25 | Male | 32 | RR-MS | Untreated |